U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Jeffrey Fisher
  1. National Center for Toxicological Research

Jeffrey Fisher Ph.D.

Jeffrey Fisher

 

Research Toxicologist — Division of Biochemical Toxicology

Jeffrey Fisher
Jeffrey Fisher, Ph.D.

(870) 543-7391
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigator page


About  |  Publications  |  Lab Member


Background

Dr. Jeffrey Fisher is a research toxicologist in NCTR’s Division of Biochemical Toxicology. He was formerly a professor in the Department of Environmental Health Science, College of Public Health at the University of Georgia (UGA). He joined UGA in 2000 and served as department head of the Department of Environmental Health Sciences from 2000-2006 and director of the Interdisciplinary Toxicology Program at UGA from 2006-2010. Before this, he spent 25 years at the Toxicology Laboratory, Wright Patterson AFB, where he was principal investigator and senior scientist in the Toxics Hazards Division and technical advisor for the Operational Toxicology Branch. Dr. Fisher has 30 years of experience in physiological modeling and has trained graduate students and postdoctoral fellows on the concepts and application of physiological models. He was a visiting scientist at the Chemical Industry Institute of Toxicology in 1996 and at the NIOSH Taft Laboratory in 1999. During this time, he also served as an adjunct professor in the Department of Pharmacology and Toxicology at Wright State University. Dr. Fisher has published over 170 papers on pharmacokinetics and PBPK modeling in laboratory animals and humans. 
Dr. Fisher has served on several national panels and advisory boards for the Department of Defense, the Agency for Toxic Substances and Disease Registry, the Environmental Protection Agency (EPA) and nonprofit organizations. He was a U.S. delegate for the North Atlantic Treaty Organization in Paris, France, charged with evaluating the potential impact of oil-well fires on community health. Dr. Fisher served on the International Life Sciences Institute Steering Committee that evaluated chloroform and dichloroacetic acid using proposed EPA Carcinogen Risk Guidelines. He is the past president of the Biological Modeling Specialty Section of the Society of Toxicology and has served as reviewer for several toxicology journals. Dr. Fisher also was co-principal investigator on a National Institutes of Health (NIH)-supported workshop on Mathematical Modeling at the University of Georgia in the fall of 2003. He was a member of the National Academy of Sciences Subcommittee on Acute Exposure Guideline Levels from 2004-2010 and a member of the Science Advisory Board for the EPA from 2007-2010. He is an ad-hoc member of the EPA Science Advisory Board and Science Advisory Panel for dioxin, perchlorate, and chlorpyrifos. He is a fellow of the Academy of Toxicological Sciences and an associate editor for Toxicological Sciences. Dr. Fisher has a bachelor's degree in biology from the University of Nebraska at Kearney, an master's degree in biology from Wright State University, and a Ph.D. in zoology/toxicology from Miami University.

Research Interests

Dr. Fisher's career research interests are in the development and application of pharmacokinetic and biologically based mathematical models to ascertain health risks from environmental, occupational, and foodborne chemicals. Recently he has become involved in the use of physiologically based pharmacokinetic (PBPK) models for pediatric drugs. Dr. Fisher’s chemical-toxicology modeling experience includes working with chlorinated and non-chlorinated solvents, hydrocarbon-based and synthetic fuels, pesticides, perchlorate, and Bisphenol A. He has developed PBPK models for use in:

  • cancer risk assessment
  • estimating lactational transfer of solvents
  • understanding in utero and neonatal dosimetry
  • quantifying the metabolism of solvent and fuel mixtures
  • developing biologically motivated models for the hypothalamic-pituitary-thyroid axis in rodents and humans, including life stages and reproductive states. 

Dr. Fisher is best known for his pioneering laboratory research and PBPK modeling of pregnancy and lactation to describe the influence of reproductive state and life stages on the dosimetry of the solvent trichloroethylene and its primary metabolites. More recently he is recognized for creating biologically based models to describe endocrine disruption of the thyroid system during development in the rat and human and their application in safety assessment.

Since arriving at FDA, Dr. Fisher has collaborated with scientists from other FDA centers interested in using models for pediatric populations, medical devices, in vitro to in vivo extrapolation, and safety assessments for chemicals. He is involved in EPA-directed virtual thyroid-modeling projects. Dr. Fisher is collaborating with FDA and EPA scientists, industry scientists, and academia scientists to construct a robust physiological description of the preterm infant born over a range of gestational ages. Preterm birth has been overlooked in the fields of toxicology and pharmacology. The preterm neonate PBPK model will be used for estimating drug dosage and exposure to chemicals used in baby products. Dr. Fisher will carry out modeling projects as proof-of-concept for in silico predictions and extrapolation of preclinical toxicology data in laboratory animals to humans. Species and life-stage extrapolation of pharmacodynamic models for diseases (e.g., hypothyroidism) will be completed over the next two years. 

Professional Societies/National and International Groups

Biological Modeling Specialty Section
Vice President-Elect
2016

Federal Insecticide, Fungicide, and Rodenticide Act Science Advisory Panel for Chlorpyrifos (EPA)
Member
2016

ILSI-HESI Working Group (EPA)
Steering Group
2015

ILSI-HESI Working Group (FDA)
Member
2016

Integrated Risk Information System Panel for Polychlorinated Biphenyls (EPA)
Member
2015

Pediatric Transporter Working Group (NIH)
Member
2014 – 2015

Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia
Adjunct Professor
2011 – Present

Science Advisory Board for Perfluorooctanoic Acid and Perfluorooctane Sulfonate (EPA)
Member
2014

Society of Toxicology
Member
2012 – Present 

Toxicological Sciences
Associate Editor
2012 – Present

BACK TO TOP


Selected Publications

A Biokinetic Model For Nickel Released From Cardiovascular Devices.
Saylor D., Adidharma L., Fisher J. and Brown R.
Regul Toxicol Pharmacol. 2016 Oct, 80:1-8. Epub 2016 May 18.  

Physiologically Based Pharmacokinetic Prediction of Linezolid and Emtricitabine in Neonates and Infants.
Duan P., Fisher J., Yoshida K., Zhang L., Burckart G. and Wang J.
Clin Pharmacokinet. 2016 Sep 6, [Epub ahead of print]  

Dietary Iodine Sufficiency and Moderate Insufficiency in the Lactating Mother and Nursing Infant: A Computational Perspective.
Fisher J., Wang J., George N., Gearhart J. and McLanahan E.
PLoS One. 2016 Mar 1, 11(3):e0149300. eCollection 2016. 

Development Of A Physiologically Based Pharmacokinetic Model For Assessment Of Human Exposure To Bisphenol A.
Yang X., Doerge D., Teeguarden J. and Fisher J.
Toxicol Appl Pharmacol. 2015 Dec 15, 289(3):442-56. Epub 2015 Oct 29. 

Application Of Physiologically-Based Pharmacokinetic Modeling To Explore The Role Of Kidney Transporters In Renal Reabsorption Of Perfluorooctanoic Acid In The Rat.
Worley R. and Fisher J.
Toxicol Appl Pharmacol. 2015 Dec 15, 289(3):428-41. Epub 2015 Nov 6.  

Development Of A Physiologically-Based Pharmacokinetic Model Of 2-Phenoxyethanol And Its Metabolite Phenoxyacetic Acid In Rats And Humans To Address Toxicokinetic Uncertainty In Risk Assessment.
Troutman J., Rick D., Stuard S., Fisher J. and Bartels M. 
Regul Toxicol Pharmacol. 2015 Nov, 73(2):530-43. Epub 2015 Jul 16. 

A Survey of Neonatal Pharmacokinetic and Pharmacodynamic Studies in Pediatric Drug Development.
Wang J., Avant D., Green D., Seo S., Fisher J., Mulberg A., McCune S. and Burckart G.
Clin Pharmacol Ther. 2015 Sep, 98(3):328-35. Review. 

Quantitative Global Sensitivity Analysis Of A Biologically Based Dose-Response Pregnancy Model For The Thyroid Endocrine System.
Lumen A., McNally K., George N., Fisher J. and Loizou G.
Front Pharmacol. 2015 May 27, 6:107. eCollection 2015.  

Unraveling Bisphenol A Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling.
Yang X. and Fisher J.
Front Pharmacol. 2015 Jan 9, 5:292. eCollection 2014. 

Development Of A Physiologically Based Model To Describe The Pharmacokinetics Of Methylphenidate In Juvenile And Adult Humans And Nonhuman Primates.
Yang X., Morris S., Gearhart J., Ruark C., Paule M., Slikker W., Mattison D., Vitiello B., Twaddle N., Doerge D., Young J. and Fisher J.
PLoS One. 2014 Sep 3, 9(9):e106101. eCollection 2014.  

The Hypothalamic-Pituitary-Thyroid Axis In Infants And Children: Protection From Radioiodines.
Fisher J., Yang X., Harris C., Koturbash I. and Lumen A.
J Thyroid Res. 2014, 2014:710178. Epub 2014 May 25. Review.

Estimation Of Placental And Lactational Transfer And Tissue Distribution Of Atrazine And Its Main Metabolites In Rodent Dams, Fetuses, And Neonates With Physiologically Based Pharmacokinetic Modeling.
Lin Z., Fisher J., Wang R., Ross M. and Filipov N.
Toxicol Appl Pharmacol. 2013 Nov 15, 273(1): 140-58. Epub 2013 Aug 17. 

Prediction And Evaluation Of Route Dependent Dosimetry Of BPA In Rats At Different Life Stages Using A Physiologically Based Pharmacokinetic Model.
Yang X., Doerge D. and Fisher J.
Toxicol Appl Pharmacol. 2013 Jul 1, 270(1):45-59. Epub 2013 Apr 6.

Prediction and Evaluation of Route Dependent Dosimetry of BPA in Rats at Different Life Stages using a Physiologically Based model.
Yang X., Doerge D. and Fisher J.
Toxicol. Appl. Pharmacol. 2013, 270, 45-59.

Evaluation Of Perturbations In Serum Thyroid Hormones During Human Pregnancy Due To Dietary Iodide And Perchlorate Exposure Using A Biologically Based Dose-Response Model.
Lumen A., Mattie D. and Fisher J.
Toxicol Sci. 2013 Jun, 133(2):320-41. Epub 2013 Mar 27.  

Evaluation Of Iodide Deficiency In The Lactating Rat And Pup Using A Biologically Based Dose-Response Model.
Fisher J., Li S., Crofton K., Zoeller R., McLanahan E., Lumen A. and Gilbert M.
Toxicol Sci. 2013 Mar, 132(1):75-86. Epub 2013 Jan 3. 

An Animal Model Of Marginal Iodine Deficiency During Development: The Thyroid Axis And Neurodevelopmental Outcome.
Gilbert M., Hedge J., Valentín-Blasini L., Blount B., Kannan K., Tietge J., Zoeller R., Crofton K., Jarrett J. and Fisher J.
Toxicol Sci. 2013 Mar, 132(1):177-95. Epub 2013 Jan 3.
 

BACK TO TOP

Lab Member

Lydia Bilinsky, Ph.D.
ORISE Postdoctoral Fellow
(870) 543-7391
NCTRResearch@fda.hhs.gov

BACK TO TOP


Contact Information
Jeffrey Fisher
(870) 543-7391
Expertise
Approach